Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

[...]it has been reported that lenvatinib was initiated immediately after the failure of anti-PD-1/PD-L1 therapy, which is expected to have a more potent anti-tumor effect due to synergism than when initiated alone as first-line therapy [4]. [...]of previous therapy, treatment with lenvatinib would...

Full description

Saved in:
Bibliographic Details
Published inLiver cancer (Basel ) Vol. 11; no. 2; pp. 174 - 177
Main Authors Johira, Yusuke, Kawaoka, Tomokazu, Kosaka, Masanari, Shirane, Yuki, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Imamura, Michio, Sentani, Kazuhiro, Oue, Naohide, Arihiro, Koji, Kuroda, Shintaro, Kobayashi, Tsuyoshi, Ohdan, Hideki, Chayama, Kazuaki, Aikata, Hiroshi
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 01.04.2022
Karger Publishers
Subjects
Cancer
Conflicts of interest
Hepatectomy
Letter to the Editor
Liver cancer
Magnetic resonance imaging
Mutation
Patients
Response rates
Thrombocytopenia
Thrombosis
Tomography
Veins & arteries
Japan
Online AccessGet full text

Cover

More Information
Summary:[...]it has been reported that lenvatinib was initiated immediately after the failure of anti-PD-1/PD-L1 therapy, which is expected to have a more potent anti-tumor effect due to synergism than when initiated alone as first-line therapy [4]. [...]of previous therapy, treatment with lenvatinib would be appropriate. Conflict of Interest Statement The authors have no conflicts of interest to declare.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2235-1795
1664-5553
DOI:10.1159/000520898